This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Measures of G-cell function can serve as the primary end point of clinical trials attempting to slow or stop G-cell destruction. There are numerous ways to assess this as the G-cell responds to various oral and IV secretagogues. The two most commonly used tests are the C-peptide responses to an oral mixed meal (Mixed Meal Tolerance Test, MMTT) and to administration of IV glucagon (Glucagon Stimulation Test, GST). These tests differ in duration, type and route of stimulous, degree of hyperglycemia induced, and subject and investigator burden. It is not known whether there are differences in reliability between the two tests. Thus, determination of reliability of C-peptide measures under these test conditions will be the primary outcome. These tests will be done in the Clinical Research Centers of the TrialNet Clinical Centers to assure the highest accuracy and reliability of the tests.
Showing the most recent 10 out of 724 publications
